tetano
Editor, Senior Moderator
Am J Trop Med Hyg
. 2021 May 18;tpmd210164.
doi: 10.4269/ajtmh.21-0164. Online ahead of print.
Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study
Ramachandran Thiruvengadam[SUP] 1 [/SUP], Souvick Chattopadhyay[SUP] 1 [/SUP], Farha Mehdi[SUP] 1 [/SUP], Bapu Koundinya Desiraju[SUP] 1 [/SUP], Susmita Chaudhuri[SUP] 1 [/SUP], Savita Singh[SUP] 1 [/SUP], Vandita Bhartia[SUP] 1 [/SUP], Pallavi Kshetrapal[SUP] 1 [/SUP], Uma Chandra Mouli Natchu[SUP] 2 [/SUP], Nitya Wadhwa[SUP] 1 [/SUP], Shailaja Sopory[SUP] 1 [/SUP], Mudita Wahi[SUP] 1 [/SUP], Anil K Pandey[SUP] 3 [/SUP], Juhi Taneja[SUP] 3 [/SUP], Nidhi Anand[SUP] 3 [/SUP], Nandini Sharma[SUP] 4 [/SUP], Pragya Sharma[SUP] 4 [/SUP], Sonal Saxena[SUP] 4 [/SUP], Deepa Sindhu[SUP] 5 [/SUP], Brahmdeep Sindhu[SUP] 6 [/SUP], Dharmendra Sharma[SUP] 1 [/SUP], Tripti Shrivastava[SUP] 1 [/SUP], Arjun Dang[SUP] 7 [/SUP], Gaurav Batra[SUP] 1 [/SUP], Gagandeep Kang[SUP] 1 8 [/SUP], Shinjini Bhatnagar[SUP] 1 [/SUP], DBT India Consortium for COVID 19 Research
Affiliations
Abstract
Clinical and epidemiological characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now widely available, but there are few data regarding longitudinal serology in large cohorts, particularly those from low-income and middle-income countries. We established an ongoing prospective cohort of 3,840 SARS-CoV-2-positive individuals according to RT-PCR in the Delhi-National Capital Region of India to document clinical and immunological characteristics during illness and convalescence. The immunoglobulin G (IgG) responses to the receptor binding domain (RBD) and nucleocapsid were assessed at 0 to 7 days, 10 to 28 days, and 6 to 10 weeks after infection. The clinical predictors of seroconversion were identified by multivariable regression analysis. The seroconversion rates during the postinfection windows of 0 to 7 days, 10 to 28 days, and 6 to 10 weeks were 46%, 84.7%, and 85.3%, respectively (N = 743). The proportion with a serological response increased with the severity of coronavirus disease 2019 (COVID-19). All participants with severe disease, 89.6% with mild to moderate infection, and 77.3% of asymptomatic participants had IgG antibodies to the RBD antigen. The threshold values for the nasopharyngeal viral RNA RT-PCR of a subset of asymptomatic and symptomatic seroconverters were comparable (P = 0.48) to those of nonseroconverters (P = 0.16) (N = 169). This is the first report of longitudinal humoral immune responses to SARS-CoV-2 over a period of 10 weeks in South Asia. The low seropositivity of asymptomatic participants and differences between assays highlight the importance of contextualizing the understanding of population serosurveys.
. 2021 May 18;tpmd210164.
doi: 10.4269/ajtmh.21-0164. Online ahead of print.
Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study
Ramachandran Thiruvengadam[SUP] 1 [/SUP], Souvick Chattopadhyay[SUP] 1 [/SUP], Farha Mehdi[SUP] 1 [/SUP], Bapu Koundinya Desiraju[SUP] 1 [/SUP], Susmita Chaudhuri[SUP] 1 [/SUP], Savita Singh[SUP] 1 [/SUP], Vandita Bhartia[SUP] 1 [/SUP], Pallavi Kshetrapal[SUP] 1 [/SUP], Uma Chandra Mouli Natchu[SUP] 2 [/SUP], Nitya Wadhwa[SUP] 1 [/SUP], Shailaja Sopory[SUP] 1 [/SUP], Mudita Wahi[SUP] 1 [/SUP], Anil K Pandey[SUP] 3 [/SUP], Juhi Taneja[SUP] 3 [/SUP], Nidhi Anand[SUP] 3 [/SUP], Nandini Sharma[SUP] 4 [/SUP], Pragya Sharma[SUP] 4 [/SUP], Sonal Saxena[SUP] 4 [/SUP], Deepa Sindhu[SUP] 5 [/SUP], Brahmdeep Sindhu[SUP] 6 [/SUP], Dharmendra Sharma[SUP] 1 [/SUP], Tripti Shrivastava[SUP] 1 [/SUP], Arjun Dang[SUP] 7 [/SUP], Gaurav Batra[SUP] 1 [/SUP], Gagandeep Kang[SUP] 1 8 [/SUP], Shinjini Bhatnagar[SUP] 1 [/SUP], DBT India Consortium for COVID 19 Research
Affiliations
- PMID: 34003792
- DOI: 10.4269/ajtmh.21-0164
Abstract
Clinical and epidemiological characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now widely available, but there are few data regarding longitudinal serology in large cohorts, particularly those from low-income and middle-income countries. We established an ongoing prospective cohort of 3,840 SARS-CoV-2-positive individuals according to RT-PCR in the Delhi-National Capital Region of India to document clinical and immunological characteristics during illness and convalescence. The immunoglobulin G (IgG) responses to the receptor binding domain (RBD) and nucleocapsid were assessed at 0 to 7 days, 10 to 28 days, and 6 to 10 weeks after infection. The clinical predictors of seroconversion were identified by multivariable regression analysis. The seroconversion rates during the postinfection windows of 0 to 7 days, 10 to 28 days, and 6 to 10 weeks were 46%, 84.7%, and 85.3%, respectively (N = 743). The proportion with a serological response increased with the severity of coronavirus disease 2019 (COVID-19). All participants with severe disease, 89.6% with mild to moderate infection, and 77.3% of asymptomatic participants had IgG antibodies to the RBD antigen. The threshold values for the nasopharyngeal viral RNA RT-PCR of a subset of asymptomatic and symptomatic seroconverters were comparable (P = 0.48) to those of nonseroconverters (P = 0.16) (N = 169). This is the first report of longitudinal humoral immune responses to SARS-CoV-2 over a period of 10 weeks in South Asia. The low seropositivity of asymptomatic participants and differences between assays highlight the importance of contextualizing the understanding of population serosurveys.